drugset / Trial / NCT00514137
Sunitinib in Treating Patients With Relapsed Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial is studying how well sunitinib works in treating patients with relapsed multiple myeloma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer
Timeline
- Start
- 2007-09
- Primary completion
- 2009-03
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |